Press Releases for GILD

Press Releases
Achillion Reports Third Quarter Results
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
Stocks This Morning: Dragon Capital Group - August 26, 2009
StockPreacher.com Issues Trading Outlook for Cell Therapeutics Inc.
Gilead Announces Senior Management Promotion
EFI Reports Q2 2009 Results
Kevin E. Lofton Joins Gilead Sciences’ Board of Directors
Gilead Sciences Announces Record Second Quarter 2009 Financial Results
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada® and TMC278
InvestorSoup.com Issues Trading Outlook for Hemispherex Biopharma Inc.
Gilead Sciences to Release Second Quarter 2009 Financial Results on Tuesday, July 21, 2009
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
Gilead Sciences to Present at Two Upcoming Investor Conferences
Biotech Shows Glimmer of an Upward Trend
Depomed Names Shay Weisbrich Vice President of Marketing
Gilead Sciences’ Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency
Gilead Sciences Announces Changes to Cardiovascular R&D Organization Leadership
New Data for Gilead Sciences’ Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
Achillion Reports First Quarter Financial Results and Provides Pipeline Update
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes
Gilead Sciences’ Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives
Gilead Sciences Announces Record First Quarter 2009 Financial Results
Gilead Sciences Completes Acquisition of CV Therapeutics
Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered
Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
Phase III Data for Gilead Sciences’ Darusentan Accepted as Late-Breaker Presentation at ASH 2009
Gilead Sciences Announces Notification of ANDA Filing for Atripla®
Beacon Equity Issues Trade Alerts on Market Movers: BBI, SVNT, SI, GILD, CHRS, RIMM
Phase III Study of Gilead’s Darusentan for Resistant Hypertension Meets Primary Endpoints
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
S&P 500 Stock Buybacks Retreat 66% in Fourth Quarter; Off 42% in 2008 - Mar 26 2009 11:36AM
Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Zacks Analyst Blog Highlights: Analog Devices Inc., Gilead Sciences, CV Therapeutics, Koninklijke Philips Electronics N.V., And Skyworks Solutions, Inc.
European CHMP Adopts Negative Opinion on Aztreonam Lysine
CV Therapeutics' Board of Directors Recommends Stockholders Accept Gilead Sciences' $20.00 per Share Cash Tender Offer
Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences
Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics
Zacks Analyst Blog Highlights: Gilead Sciences, CV Therapeutics, The Boeing Co, Northrop Grumman Corp and eBay Inc.
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
CORRECTING and REPLACING Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16
Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16
Gilead Sciences to Present at the Barclays Capital Global Healthcare Conference on Tuesday, March 10
Gilead Receives Response From U.S. FDA on Company’s Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
Stock Preacher Issues Technical Trade Alerts on: GILD, WFC, FCX, GS, WMT
Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350
Gilead Sciences to Present at the 11th Annual BIO CEO Investor Conference on Tuesday, February 10
Zacks #1 Rank Top Performers: LaBranche & Co., Open Text Corporation, Multi-Fineline Electronix, Gilead Sciences, Inc. And Novo Nordisk
Gilead Announces Senior Management Promotion
Zacks Analyst Blog Highlights: Ultrapar ParticipaÃ§ÃµEs S.A., Corrections Corp. Of America, Gilead Sciences, Inc., Dr. Pepper Snapple Group Inc. And VistaPrint Limited.
Zacks Analyst Blog Highlights: Ultrapar Participacoes S.A., Corrections Corp. Of America, Gilead Sciences, Inc., Dr. Pepper Snapple Group Inc. And VistaPrint Limited.
BetterInvesting Magazine Releases April's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use - Jan 30 2009 8:21PM
EFI Closes Sale of Real Estate Assets to Gilead Sciences
Gilead Completes Acquisition of Building and Associated Land from EFI
Zacks Bull & Bear of the Day Highlights: VistaPrint, Trimeris, Newmont Mining, Kinross Gold and Gilead Sciences
BenchmarkJournal.Com (Complimentary) Analyst Review for MW, VPRT, RFMD and GILD
Gilead Outlines R&D Priorities for 2009
Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009
Portfolios Rise As "Stock Alert" Trades Continue 96%+ Profitable Streak
Gilead Sciences to Present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12
OneChicago Reports December Volume
Zacks Analyst Blog Highlights: Sara Lee Corporation, Burger King Holdings, Inc., McDonald's, Gilead Sciences, Inc., And ICICI Bank Limited.
Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
Standard & Poor's Announces Changes to U.S. Indices - 11-12-08
Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Data Demonstrating Significant Efficacy of Viread® in Treating Chronic Hepatitis B Published in New England Journal of Medicine
Gilead Sciences to Present at Two Upcoming Investor Conferences - Nov 25 2008 4:21PM
Gilead Sciences Announces Notification of ANDA Filing for Truvada
Deloitte Unveils 2008 Technology Fast 500 Ranking
Gilead Sciences to Present at Three Upcoming Investor Conferences
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B
Technologies, Markets and the Competitive Environment of Drug Delivery Using Nanotechnologies Explored - Oct 31 2008 11:56PM
Technologies, Markets and the Competitive Environment of Drug Delivery Using Nanotechnologies Explored - Oct 31 2008 6:56AM
Gilead Sciences to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4
Gilead Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus
EFI Reaches Agreement to Sell Real Estate Assets
Zacks Analyst Blog Highlights: Cemex S.A. De C.V., Baxter International Inc., Web.Com, Gilead Sciences, Inc. And Pfizer Inc.
Gilead Sciences Announces Third Quarter 2008 Financial Results
Seven Summits Research Releases Comments on KO, GILD, NUE, JNJ and UTX
Gilead Sciences to Release Third Quarter 2008 Financial Results on Thursday, October 16, 2008
Seven Summits Research Releases Alerts on RIG, MCD, APA, GILD, and GD
Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhalation, an Investigational Treatment for Cystic Fibrosis
Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics
Stock Market Alerts' Watch List for Thursday: GSAE! September 11, 2008
Gilead Sciences to Present at Two Upcoming Investor Conferences - Sep 10 2008 5:44PM
Seven Summits Research Releases Alerts on POT, JPM, GILD, LMT, and ICE
BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3
BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Seven Summits Research Releases Alerts on GOOG, MS, GILD, MMM, and AGU
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Richard J. Whitley, MD Joins Gilead Sciences' Board of Directors
Market Watch for Tuesday, July 29, 2008: PSTI Achieving Milestones!